Division of Rheumatology

Achievements and Future Directions

Major Achievements

Dr Cividino was promoted to Clinical Professor, is now the Director MF5, is an elected AFP committee rep, and has taken on the position as Head of Service HHHS for Rheumatology. Dr. Cividino Chairs the Scientific Committee for the CRA.

Dr. Khalidi received a Clinician-teacher Award based on his excellent teaching sessions with the residents.

Dr. Adachi has been awarded the Alliance for Better Bone Health Chair in Rheumatology. This will aid with his research in the structure of bone in osteoporosis and osteoarthritis.

In collaboration with Dr. Papaioannou, a CIHR sponsored Bone Scholar program has been instituted in Hamilton as part of an overall program involving McGill University, McMaster University and the University of Calgary. We have been successful in being awarded a number of scholarships from this program. In addition to our collaboration, Dr. Papaioannou has been cross appointed to the division of rheumatology and has been awarded a CIHR Chair in partnership with Eli Lilly.

Our research work has lead to funding of many of our trainees. Karen Beattie has completed her Canadian Arthritis Network fellowship and has received a CIHR Bone Scholar Award to further her post doctorate studies in osteoarthritis.

Future Directions

We plan to continue with our research in areas of clinical expertise. Osteoarthritis, osteoporosis and rheumatoid arthritis research will be a major focus in the coming years. We now have the infrastructure to move forward. Dr. Bensen and Dr. Cividino provide the clinical expertise, Dr. Chris Gordon, a consultant recruited from UCSF, and Dr. Dean Inglis, an engineer with structural expertise, act as our technical experts. They will help with the development of the necessary software programs to measure cartilage thickness and bone microarchitecture using basic x-rays, pQCT and pMRI. In collaboration with Dr. J. Duryea from Brigham and Women's Hospital, they have already developed the software responsible for measurement of joint space narrowing using plain x-rays of the hip and knee, and the software for the measurement of the microarchitecture of bone using pQCT and pMRI. Our pQCT work has already resulted in awards in our osteoporosis research and similar success is anticipated in our osteoarthritis work. These will serve as primary outcome measures in future clinical studies. Given our clinical expertise and patient volume, our newly developed expertise in early detection in a high risk group of osteoporosis and osteoarthritis patients using pQCT and pMRI technology, the recent development of a sensitive outcome measure for measuring the progression of osteoarthritis with x-ray and MRI, and our excellent record of attracting industry and peer-reviewed funding, we plan to focus our future research on osteoporosis and osteoarthritis. Recent research utilizing pMRI for the detection of abnormalities in the hands of patients with rheumatoid arthritis has yielded interesting results that should of benefit in understanding the early progression of erosions in these patients. Further research into quantitating erosions in RA is ongoing.

In addition, Dr W F Kean, Head of Service at Hamilton Health Sciences has a major interest in the diagnosis and management of osteoarthritis and musculoskeletal pain. He is on the editorial board of 2 European based Pharmacology Journals and publishes in the fields of OA, and OA related pharmacology. He is a regular speaker at European rheumatology venues. His interests in pain research will strengthen the work that is ongoing in Hamilton.